ESPR vs SBAC · rev $332.3M vs P/E 30, rev $1.42B
Esperion Therapeutics Inc (ESPR) versus SBA Communications Corp (SBAC) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SBA Communications Corp (SBAC) is a reit - specialty company listed on US.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported SBAC revenue for 2026-06-30 was $1.42B. Net income was $383.6M. SBAC currently screens at market cap $24.58B and trailing P/E 30.3.
ESPR currently screens at market cap $816.9M. SBAC currently screens at market cap $24.58B and trailing P/E 30.3.
Not investment advice. Open the ESPR and SBAC stock pages for the full models.
Not investment advice.